Enhanced immune priming with spatial distribution of paracrine cytokine vaccines

Journal of Immunotherapy

Volumn 19, Issue 3, 1996, Pages 176-183

  Jaffee, Elizabeth M ^a,b   Thomas, Matthew C ^a   Huang, Alex Y C ^a   Hauda, Karen M ^a   Levitsky, Hyam I ^a   Pardoll, Drew M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Ross Building ^*  (United States)

Author keywords

Gene transfer; Tumor immunology; Tumor vaccines; Vaccine administration

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; GENE TRANSFER; GENETIC TRANSDUCTION; IMMUNE RESPONSE; MELANOMA B16; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNIZATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; VACCINES, SYNTHETIC;

EID: 0030018288     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199605000-00002     Document Type: Article

References (24)

1. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
2. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
3. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 199;172:1217-24.
4. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503-12.
5. Hock H, Dorsch M, Diamantstein T, Blankenstein T. Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J Exp Med 1991;174:1291-8.
6. Asher AL, Mule JJ, Kasid A, et al. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. J Immunol 1991;146:3227-34.
7. Dranoff G, Jaffee EM, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific and long lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
8. Porgador A, Tzehoval E, Katz A, et al. Interleukin-6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992;52:3679-86.
9. Colombo MP, Ferrari G, Stoppacciaro A, et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991;173:889-97.
10. Inaba K, Steinman RM, Pack M, et al. Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med 1992;175:1157-67.
11. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176:1693-702.
12. Berns A, Cohen L, Donehower RC, et al. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma: recombinant DNA Advisory Committee Protocol. Hum Gene Ther 1995;6:347-68.
13. Fidler IJ. Biological behavior of malignant melanoma cells correlates to their survival in vivo. Cancer Res 1975;35:218-34.
14. Wolfel T, Hauer M, Klehmann E, et al. Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). Int J Cancer 1993;55:237-42.
15. Knuth A, Wolfel T, Klehmann E, Boon T, Meyer zum BKH. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci USA 1989;86:2804-8.
16. Van Der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized cytotoxic T lymphocytes on a human melanoma. Science 1991;254:1643-8.
17. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-95.
18. Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-9.
19. Bakker ABH, Schreurs MWJ, de Boer AJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994;179:1005-9.
20. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;1:3515-9.
21. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytotoxic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
22. Brichard VG, Warnier G, Van Pel A, Morlighem G, Lucas S, Boon T. Individual differences in the orientation of the cytotoxic T cell response against mouse tumor P815. Eur J Immunol 1995;25:664-71.
23. Zoulek G, Lorbeer B, Kilg W, Deinhardt F. Evaluation of a reduced dose of Hepatitis B Vaccine administered intradermally. J Med Virol 1984;14:27-32.
24. Nicholson KG, Prestage H, Cole PJ, Turner GS, Bauer SP. Multisite intradermal antirabies vaccination. Lancet 1981;1:915-8.